1. Home
  2. MBIN vs MESO Comparison

MBIN vs MESO Comparison

Compare MBIN & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Merchants Bancorp

MBIN

Merchants Bancorp

HOLD

Current Price

$52.81

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$15.49

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBIN
MESO
Founded
1990
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.0B
IPO Year
2017
2005

Fundamental Metrics

Financial Performance
Metric
MBIN
MESO
Price
$52.81
$15.49
Analyst Decision
Buy
Strong Buy
Analyst Count
3
1
Target Price
$43.67
N/A
AVG Volume (30 Days)
123.8K
182.2K
Earning Date
04-28-2026
02-26-2026
Dividend Yield
0.89%
N/A
EPS Growth
N/A
N/A
EPS
2.73
N/A
Revenue
N/A
N/A
Revenue This Year
$31.76
$629.74
Revenue Next Year
$3.73
$30.65
P/E Ratio
$19.47
N/A
Revenue Growth
N/A
N/A
52 Week Low
$30.37
$13.05
52 Week High
$56.87
$21.50

Technical Indicators

Market Signals
Indicator
MBIN
MESO
Relative Strength Index (RSI) 47.83 42.83
Support Level $45.39 $15.37
Resistance Level $54.48 $16.06
Average True Range (ATR) 1.33 0.42
MACD -0.24 -0.22
Stochastic Oscillator 32.29 1.74

Price Performance

Historical Comparison
MBIN
MESO

About MBIN Merchants Bancorp

Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.

Share on Social Networks: